MedTrace Logo

Analgesic and Antihyperalgesic Effects of Morphine and Buprenorphine

NCT01296334 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2016-11-28

No results posted yet for this study

Summary

Tissue injury is associated with pain from the injured site (primary hyperalgesia) and pain from non-injured tissue in the vicinity of the trauma (secondary hyperalgesia). In the present study we investigate primary and secondary hyperalgesia in healthy volunteers following an experimental first degree burn injury.

The objectives are:

* to compare analgesic and anti-hyperalgesic effects of two opioids (morphine and buprenorphine).
* to investigate if these effects are related to the volunteers individual pain sensitivity

Conditions

Interventions

DRUG

morphine LO

intravenous infusion, 10 mg, once, 4 hours

DRUG

Morphine Hi

intravenous infusion, 20 mg, once, 4 hours

DRUG

Buprenorphine LO

intravenous infusion, 0.3 mg, once, 4 hours

DRUG

Buprenorphine Hi

intravenous infusion, 0.6 mg, once, 4 hours

OTHER

saline

intravenous infusion, 0.9% saline, once, 4 hours

Sponsors & Collaborators

  • Norpharma A/S

    collaborator INDUSTRY

  • mads u werner

    lead OTHER

Principal Investigators

  • Mads U Werner, MD, DMSc · Multidisciplinary Pain Centre 7612, Rigshospitalet, Blegdamsvej 9, DK 2100 Copenhagen O

  • Lona L Christrup, MSc, PhD · Pharmaceutical Faculty, Copenhagen University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2011-09-30
Completion
2011-10-31

Countries

  • Denmark

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01296334 on ClinicalTrials.gov